Although this is the rule when metabolic deterioration is evident, in the early stages of CFRD, when there is a minor metabolic deterioration and the nutritional status is not usually compromised, insulin therapy can represent a burden for people with CF, including by carrying the risk of hypoglycaemia, having higher costs, causing more stress, and requiring more education for its correct use. The gene discussed is INS; the disease is Hypoglycemia.